Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Dow
Johnson and Johnson
Colorcon
Medtronic

Last Updated: May 21, 2022

CLINICAL TRIALS PROFILE FOR KALYDECO


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Kalydeco

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01614457 ↗ Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT) Completed Cystic Fibrosis Foundation Phase 3 2012-07-01 The purpose of this study is to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis (CF) who have the R117H-CFTR mutation.
NCT01614457 ↗ Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT) Completed Cystic Fibrosis Foundation Therapeutics Phase 3 2012-07-01 The purpose of this study is to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis (CF) who have the R117H-CFTR mutation.
NCT01614457 ↗ Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT) Completed Vertex Pharmaceuticals Incorporated Phase 3 2012-07-01 The purpose of this study is to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis (CF) who have the R117H-CFTR mutation.
NCT01614470 ↗ Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation Completed Cystic Fibrosis Foundation Phase 3 2012-07-01 The purpose of this study is to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis (CF) who have a non-G551D cystic fibrosis transmembrane regulator (CFTR) gating mutation (any one of the following CFTR mutations: G178R, G551S, S549N, S549R, G970R, G1244E, S1251N, S1255P, or G1349D).
NCT01614470 ↗ Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation Completed Cystic Fibrosis Foundation Therapeutics Phase 3 2012-07-01 The purpose of this study is to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis (CF) who have a non-G551D cystic fibrosis transmembrane regulator (CFTR) gating mutation (any one of the following CFTR mutations: G178R, G551S, S549N, S549R, G970R, G1244E, S1251N, S1255P, or G1349D).
NCT01614470 ↗ Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation Completed Vertex Pharmaceuticals Incorporated Phase 3 2012-07-01 The purpose of this study is to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis (CF) who have a non-G551D cystic fibrosis transmembrane regulator (CFTR) gating mutation (any one of the following CFTR mutations: G178R, G551S, S549N, S549R, G970R, G1244E, S1251N, S1255P, or G1349D).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Kalydeco

Condition Name

Condition Name for Kalydeco
Intervention Trials
Cystic Fibrosis 19
Chronic Obstructive Pulmonary Disease 3
Chronic Bronchitis 2
Healthy 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Kalydeco
Intervention Trials
Cystic Fibrosis 19
Fibrosis 17
Pulmonary Disease, Chronic Obstructive 3
Lung Diseases, Obstructive 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Kalydeco

Trials by Country

Trials by Country for Kalydeco
Location Trials
United States 162
United Kingdom 10
Canada 8
Australia 7
Belgium 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Kalydeco
Location Trials
Alabama 11
Massachusetts 9
California 9
Pennsylvania 8
Missouri 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Kalydeco

Clinical Trial Phase

Clinical Trial Phase for Kalydeco
Clinical Trial Phase Trials
Phase 4 3
Phase 3 6
Phase 2 6
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Kalydeco
Clinical Trial Phase Trials
Completed 16
Recruiting 6
Unknown status 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Kalydeco

Sponsor Name

Sponsor Name for Kalydeco
Sponsor Trials
Vertex Pharmaceuticals Incorporated 13
University of Alabama at Birmingham 6
Cystic Fibrosis Foundation 5
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Kalydeco
Sponsor Trials
Other 22
Industry 19
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Merck
Boehringer Ingelheim
Dow
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.